Experimental studies demonstrated that in LN patients and lupus-prone mouse models, the selective NLRP3 inhibitor MCC950 effectively ameliorated proteinuria, renal histopathological injury, and podocyte foot process effacement (95), underscoring its therapeutic potential in podocyte protection. Here, NLRP3 is linked to lobular neoplasia.